Results 41 to 50 of about 4,918,610 (234)

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa

Pharmaceuticals, 2023
A small natural substance called cirsilineol (CSL), which was discovered in the plant Artemisia vestita, is lethal to many cancer cells and has antioxidant, anticancer, and antibacterial properties.
Go Oun Kim, Jong Beom Heo, Dong Ho Park, Gyu Yong Song, Jong-Sup Bae   +4 more
doaj   +1 more source

Sacral Neural Crest‐Derived Extracellular Vesicles Promote Pelvic Ganglion Repair Through Anti‐Pyroptotic Effects Involving ANXA1–FPR2 Signaling

Advanced Science, EarlyView.
Extracellular vesicles derived from human pluripotent stem cell‐derived sacral neural crest cells promote repair of injured major pelvic ganglia and improve colorectal function. These vesicles reduce oxidative stress and pyroptosis, with ANXA1–FPR2 signaling contributing to their protective effects, and show a favorable therapeutic profile compared ...
Ting Yang, Wenwei Liu, Hufei Wang, Yuxin Wu, Yuanchen Ma, Xiaofeng Wang, Tianxiang Lei, Qiao Tang, Yebohao Zhou, Weiqiang Li, Andy Peng Xiang, Wu Song   +11 more
wiley   +1 more source

Recombinant Tissue Factor Pathway Inhibitor Enhances the Binding of Factor Xa to Human Monocytes

, 2001
SummaryTissue factor pathway inhibitor (TFPI) is a kunitz-type inhibitor of activated factor X (Xa). TFPI was reported to mediate Xa binding to a few of carcinoma cell lines.
Fletcher Taylor, Alvin Chang, Anguo Li, Tze-Chen Wun, Glenn Peer   +4 more
core   +1 more source

Chrysanthemum Morifolium–Derived Nanovesicles Reduce Lactate‐Associated Histone Lactylation and Modulate Microglia‐Mediated Neuroinflammation in Sepsis‐Associated Encephalopathy

Advanced Science, EarlyView.
When used to treat sepsis‐associated encephalopathy, Chrysanthemum morifolium–derived nanovesicles can inhibit the H3K18la/NF‐κB axis to regulate microglia‐mediated neuroinflammation. ABSTRACT Sepsis‐associated encephalopathy (SAE)—a complication of the central nervous system in patients with sepsis—markedly diminishes cognitive functions and is linked
Kaiqiang Li, Xuling Luo, Xiaoting Zhang, Chengwen He, Wei Xu, Aibo Xu, Shushan Hua, Liping Wang, Liang Ma, Ke Hao, Youmin Ying, Zhen Wang   +11 more
wiley   +1 more source

Isolation and Characterization of Poecistasin, an Anti-Thrombotic Antistasin-Type Serine Protease Inhibitor from Leech Poecilobdella manillensis

Toxins, 2018
Antistasin, first identified as a potent inhibitor of the blood coagulation factor Xa, is a novel family of serine protease inhibitors. In this study, we purified a novel antistasin-type inhibitor from leech Poecilobdella manillensis called poecistasin ...
Xiaopeng Tang, Mengrou Chen, Zilei Duan, James Mwangi, Pengpeng Li, Ren Lai   +5 more
doaj   +1 more source

Complement Activation Linked to Type II Interferon Signaling in Still Disease

Arthritis &Rheumatology, EarlyView.
Objective Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. Although complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. Methods Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing
Freya M. C. H. Huijsmans, Tabea Thalheim, Alejandra Bodelón, Greta Rogani, Lyanne J. P. M. Sijbers, Remco G. A. Erkens, Aafke de Ligt, Rianne Scholman, Aron Brinker, Gisella B. Beretta, Nienke M. Ter Haar, Thomas Vogl, Johannes Roth, Trang T. Duong, Sytze de Roock, Joost F. Swart, Deborah A. Marshall, Susanne M. Benseler, Rae S. M. Yeung, Christoph Kessel, Sebastiaan J. Vastert, Emely L. Verweyen, Jorg van Loosdregt, on behalf of the UCAN CAN‐DU/UCAN CURE Consortia and the One Child Every Child Initiative, Adam Huber, Bianca Lang, Chelsea DeCoste, Elizabeth Stringer, Suzanne Ramsey, Alan Rosenberg, Kate Neufeld, Mehul Jariwala, Tristan Kerr, Alexander Mosoiu, Alisa Rachlis, Amy Xu, Arthur Cheng, Brenleigh Jebb, Brian Feldman, Bruno Pereira, Deborah Levy, Dilan Dissanayake, Elizaveta Limenis, Evelyn Rozenblyum, Harper Cheng, Jennifer Ji Young Lee, Lynn Spiegel, Rayfel Schneider, Ronald Laxer, Ruud Verstegen, Shirley Tse, Andrea Human, David Cabral, Herman Tam, Jaime Guzman, Kim Morishita, Kristin Houghton, Lori Tucker, Mercedes Chan, Ross Petty, Tommy Gerschman, Annet van Royen‐Kerkhof, Berent Prakken, Erika Van Nieuwenhove, Marc Jansen, Nico Wulffraat, Ciarán Duffy, Nadia Luca, Roman Jurencak, Tala El Tal, Claire LeBlanc, Gaëlle Chédeville, Piya Lahiry, Rosie Scuccimarri, Sarah Campillo, Clare Hutchinson, Daniah Basodan, Dax G Rumsey, Hon Yan Ng, Jeanine McColl, Lillian Lim, Tara McGrath, Danielle Brinkman, Petra Hissink Muller, Elizabeth Legger, Wineke Armbrust, Ellen Schatorje, Esther Hoppenreijs, Elodie Boudes, Gillian Currie, Heinrike Schmeling, Muhammed Dhalla, Nicole Johnson, Paivi Miettunen, Ravneet Sran, Rebeka Stevenson, Erkan Demirkaya, Jonathan Park, Roberta Berard, Giske Biesbroek, Mariken Gruppen, Gordon Soon, Joseph Cafazzo, Liane Heale, Michelle Batthish, Tania Cellucci, Lily Lim, Maarten IJzerman, Marinka Twilt, Marleen Verkaaik, Philomine van Pelt, Sylvia Kamphuis, Michelle Kip, Nicholas Blanchette, Paul Dancey, Regina de Geus   +115 more
wiley   +1 more source

Apixaban, an oral, direct inhibitor of activated Factor Xa

, 2008
Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase ...
Lip, Gregory, Shantsila, Eduard
core   +2 more sources

The discovery of rivaroxaban: translating preclinical assessments into clinical practice

Frontiers in Pharmacology, 2013
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants.
Dagmar eKubitza, Elisabeth ePerzborn, Scott D Berkowitz   +2 more
doaj   +1 more source

Engineering programmable peptide hydrogels for chronic refractory wounds: A mechanism‐driven framework

BMEMat, EarlyView.
To break the self‐perpetuating pathology of chronic wounds, we propose a mechanism‐driven engineering framework for peptide‐based hydrogels. This review elucidates a hierarchical strategy—from molecular design to intelligent, multi‐functional systems—that enables these programmable biomaterials to dynamically intervene in key pathological loops and ...
Xiaoyu Lv, Xinyi Chao, Jiamin Zhang, Jianfeng Liu   +3 more
wiley   +1 more source

Waste activated sludge high‐rate treatment of septage: Stabilization phase trials and comparison with winery wastewater treatment

The Canadian Journal of Chemical Engineering, EarlyView.
Performance evaluation of the waste activated sludge high‐rate (WASHR) process for septic wastewater treatment. Abstract The waste‐activated sludge high‐rate (WASHR) process is evaluated as a batch‐mode pre‐treatment for actual septage using a high‐rate contact stabilization (HRCS) approach.
Arman Shirali, Melody Blythe Johnson, Mehrab Mehrvar   +2 more
wiley   +1 more source